IFNγ-mediated CD38 up-regulation requires p38, NF-κB, and JAK/STAT.
A–D, primary AML apheresis samples (n = 3) were pretreated for 30 min with a 5 nm concentration of the JAK1/2 inhibitor ruxolitinib (A), 5 μm p38 inhibitor SB203580 (B), 5 μm NF-κB inhibitor BAY 11-7085 (C), or 25 μm ERK inhibitor U0126 (D) and then treated for 18 h with or without 10 ng/ml IFNγ. qPCR was done to measure CD38 transcript. *, p ≤ 0.05. UT, untreated. Error bars, S.D.